Print

The IGBA

In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. To reflect the evolving nature of the industry, in September 2015, IGPA incorporated under Swiss Law, and at the same time changed the name of the organization to the International Generic and Biosimilar Medicines Association (IGBA).

In 2016, IGBA was admitted as an ICH Assembly Member and in 2018 as an ICH Management Committee Member.

Since September 2019, IGBA has been an Accredited WIPO Observer and in October 2019 WHO signed a Memorandum of Understanding (MoU) with IGBA, which underscores the importance of generic and biosimilar medicines in increasing worldwide patient access to safe, effective and high-quality affordable medicines.

In addition, IGBA maintains constant dialogue with other national, regional and international bodies.

IGBA is, so far, only open to national and regional associations. It consists of Full Members and Associate Members.

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

Telephone: +32 (0)2 5346607 (S. Kox)
E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site